Tag: decentralized clinical trials
As research study sponsors and CROs look to reach clinical trial recruitment and participant retention goals, they should consider moving some trial site activities into patients’ homes. This was proven during the COVID-19 pandemic, as the use of decentralized and hybrid trials became the norm by necessity. According to the data in this article published […]
Life sciences organizations are paying closer attention to ways that improve the patient experience in clinical research trials, while also increasing trial participant enrollment and retention. According to an article by McKinsey & Company that says COVID-19 catalyzed a shift to decentralized clinical trials, typically 70% of potential trial participants live more than two hours […]
A report from Global Data was cited in a Fierce Biotech article that claims more than a quarter of rare disease trials are culled due to low patient rates. The data analytics and life science consultancy firm examined over 700 rare disease studies from 2016 to 2020 to arrive at the conclusion. How to Better […]
This insightful article by PharmaVOICE discusses how decentralized clinical trials (DCTs) reduce burdens on patients. Nicholas Kenny, Ph.D., chief scientific officer at Syneos Health says, “The key advantage is DCTs allow us to take the trial to the patient as opposed to taking the patient to the site.” The focus of the story begins by […]